Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation

YUWEN DIAO1-3*, XIAODONG WANG1,2*, YANYAN WAN1,2*, JINGJING ZHONG1,2*, DONG GAO1,2, YU LIU1,2, NINGNING GAO1,2, WANG LI1,2, BING LIU1,2, XINPING HUANG1,2, ZHENCHAO JIN1,2, BOYA PENG1,2, ZHULIN WANG1,2, LI FU1, SIPING CHEN1 and GUANGYI JIN1,2

1Cancer Research Center, National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Medicine, Shenzhen University; 2Shenzhen Engineering Laboratory of Synthetic Biology, Shenzhen, Guangdong 518060; 3Advanced Institute for Medical Sciences, Dalian Medical University, Dalian, Liaoning 116044, P.R. China

Received August 29, 2015; Accepted October 11, 2015

DOI: 10.3892/or.2015.4436

Abstract. Immunotherapy is emerging as a powerful and active tumor-specific approach against cancer via triggering the immune system. Toll-like receptors (TLRs) are fundamental elements of the immune system, which facilitate our understanding of the innate and adaptive immune pathways. TLR agonists used as single agents can effectively eradicate tumors due to their potent stimulation of innate and adaptive immunity. We examined the effects of a novel adenine type of TLR7 agonists on both innate and adaptive immune activation in vitro and in vivo. We established the local and distant tumor-bearing mice derived from murine mammary carcinoma cell line (4T1) to model metastatic disease. Our data demonstrated that SZU101 was able to stimulate innate immune cells to release cytokines at the very high level compared with LPS at the same or lower concentration. Locally intratumoral SZU101 injection can elicit a systemic antitumor effect on murine breast tumor model. SZU101 affected the frequency of intratumoral immune cell infiltration, including the percentage of CD4+ and CD8+ increase, and the ratio of Tregs decrease. Our data reveal that the antitumor effect of SZU101 is associated with multiple mechanisms, inducing tumor-specific immune response, activation of innate immune cells and modulation of the tumor microenvironment.

Introduction

Toll-like receptors (TLRs) are fundamental elements of the immune system, which facilitate our understanding of the innate and adaptive immune pathways (1). TLRs are expressed on a variety of cells, including B cells, specific types of T cells, DCs and macrophages. All the TLRs can recognize distinct molecular components of bacteria, viruses, fungi or other pathogens (1,2). Also some synthetic small molecules can activate certain TLR pathways (3). Particularly, TLR ligands can control the activation of dendritic cells (DCs), trigger the maturation program of DCs and lead to the secretion of proinflammatory cytokines (4). Most TLR ligands possess important properties that can initiate the host innate and adaptive immune response for the immunotherapy against cancer (5). They have the ability to promote tumor-specific Th1 immune response and cytotoxic T lymphocyte responses (6,7).

Most conventional cancer therapies (surgery, chemotherapy and radiation) are not tumor-specific, so immunotherapy is emerging as a powerful tumor-specific approach to cancer treatment. However, some immunotherapies are likely to have a negative influence of the tumor immune escape. Tumor cells generated occasionally can be recognized and removed as non-self by immune cells. However, cancer progression occurs as a result of a failure in immune surveillance. Increasing research effort is focused on dysfunctional immune cells and immune cells in the tumor microenvironment (8-10). The goal of cancer immunotherapy is directed not only at stimulation of innate and adaptive immune but reversal of immune dysfunction. Recent reports based on the antitumor effect of TLR agonists provide new evidence that TLR agonists can modulate the tumor microenvironment, especially the type, location, and density of immune cells. FDA has approved seven TLR agonists on cancer immunotherapy, including imiquimod (TLR7 agonists), BCG (mixed TLR2/TLR4 agonists) and glucopyranosyl lipid adjuvant (TLR4 agonists) (11). As is known that only TLR 7 ligand can be a small-molecule synthetic agonist, several synthesized low molecular weight TLR7 agonists were
found, including imidazoquinolines and purine-like molecules, to activate immune cells via the TLR7-MyD88-dependent signaling pathway (12,13). Imiquimod is being successfully used for the treatment of many primary skin tumors and cutaneous metastases as the single antitumor agent with immunostimulatory capacity (11,14).

In the present study, we examined the effects of a novel adenine type of TLR7 agonists (SZU101) on the magnitude of both innate and adapt immune activation in vitro and in vivo. We established local and distant tumor-bearing mice derived from murine mammary carcinoma cell line (4T1) to model metastatic disease. We report on the elicited antitumor effect on tumors by multiple mechanisms, inducing tumor-specific immune response, activating innate immune cells and modulation of the tumor microenvironment. We also found that intratumoral administration of SZU101 can change the tumor microenvironment and delay distant tumor growth.

Materials and methods

Cell line and mice. The 4T1 were maintained in our lab and cultured in RPMI-1640, supplemented with 10% fetal bovine serum (FBS), 100 µg/ml penicillin and 100 µg/ml streptomycin (all from Hyclone, Logan, UT, USA). Cells were cultured at 37˚C in a humidified atmosphere with 5% CO₂. Female BALB/c mice at 6 weeks of age were purchased from the Medical Laboratory Animal Centre, Guangdong, China. All animals were housed in laminar flow cages and were permitted ad lib access to sterile food and water. The experiments were carried out in accordance with recommendations cited in the Guide for the Care and Use of Laboratory Animals of the Medical Laboratory Animal Center of Guangdong, China.

Synthesis of TLR7 agonist. TLR7 agonist (SZU101) was synthesized in our laboratory according the following scheme (15).

Mouse model and treatments. The animals were injected subcutaneously with 100 µl of 1.5x10⁵ 4T1 cells in PBS. The first injection was on day 0 in the right flank, and the second injection was on day 3 in the left flank. Mice were randomized at day 7 after inoculation to treatment by intratumoral injection with 0.1 ml of 1 mg/ml (~5 mg/kg) TLR7 agonist or placebo control (PBS, pH 7.2) 4T1 agonist or placebo (PBS, pH 7.2) in the right flank tumor every three days. Mice were sacrificed on day 30.

Western blot analysis. Cells were lysed by Cell Lysis Buffer (Beyotime Institute of Biotechnology, China). Total protein was measured with a BCA assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Samples were loaded onto SDS-polyacrylamide gels, transferred onto microporous polyvinylidene difluoride membranes and incubated with appropriate antibodies. Blotting was performed with the following primary antibodies: IκBα, NF-κBp65, mTLR7, β-actin and GAPDH, horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody (1:1,500 dilution; Cell Signaling Technology, Inc., Danvers, MA, USA). Protein bands were visualized using ECL substrate (Pierce, Rockford, IL, USA).

Determination of cytokine production in vitro. Mouse spleen lymphocytes, BMDC and NK cells were isolated from BALB/c mice and grown in RPMI-1640 medium with 10% FBS. Cells were seeded in 24-well plates at a density of 5x10⁴ cells per well. For spleen lymphocytes and NK cells, compounds were added to 24-h cultures at a final concentration ranging from 5 to 100 µM or as otherwise indicated. For BMDC, compounds were added to 6-day cultures, and they were incubated for 24 h, culture supernatants were collected and assayed for cytokine inductions by enzyme-linked immunosorbent assay (ELISA) (eBioscience, Inc., San Diego, CA, USA), according to the manufacturer's instructions. Murine macrophage-like cell line, RAW264.7, cells was used as murine macrophage to determine the cytokines. The data were calculated from triplicate wells and are presented as a mean ± SD.

Determinations of antibody titers. On day 30, mice were sacrificed, blood samples were collected from the mice and centrifuged at 3,000 x g for 15 min to obtain serum samples. Antibody titers in serum were determined by ELISA method using an alkaline phosphate-conjugated detection antibody (Millipore, Billerica, MA, USA) for 4T1 antibody, IgG1 and IgG2a.

Determinations of CTL. At the time of sacrifice, lymphocytes, separated from the spleen of each mouse by Mouse Lymphocyte Separation medium (Dakewe, Beijing, China), were used as effectors. 4T1 tumor cells were used as target cells and incubated with lymphocytes for 4 h at an effector-to-target cell ratio of 100:1. Cytotoxicity was also measured by LDH method using Non-Radioactive Cytotoxicity assay (Promega, Madison, WI, USA), according to the supplier's manual.

Determinations of ADCC. At the time of sacrifice, serum samples from the mice were 1:25 diluted, and incubated with 4T1 tumor cells for 30 min at 37˚C. NK cells, isolated from normal BALB/c mouse by Mouse NK cells Separation kit (Hao Yang, Tianjin, China), were used as effectors and seeded with the antibody-labeled 4T1 cells for 4 h at an effector-to-target cell ratio of 30:1. Cytotoxicity was measured by LDH method using Non-Radioactive Cytotoxicity assay (Promega), according to the supplier's manual. Briefly, after incubation, culture supernatants were transferred to an ELISA plate, followed by the addition of substrate solution for 30 min at room temperature. Finally, stop solution was filled in, and the optical density was measured at 490 nm with a spectrophotometer (BioTek, Winooski, VT, USA).

Flow cytometric analysis (16). On day 30, mice were sacrificed. Spleens were homogenized by repeated pipetting and filtered through a 70-µm nylon filter. Tumors from each group were minced with scissors prior to incubation with 1 mg/ml final concentration clostridiopeptidase A (Sigma-Aldrich, St. Louis, MO, USA), 0.25% trypsin (Hyclone) and 0.2 mg/ml DNase (Sigma) for 30 min at 37˚C. Single cell suspensions of splenocytes and tumors were collected and washed with FACS (5% calf serum in PBS) 3 times and incubated with FACS for 1 h, stained with appropriate antibodies at 1 µg/ml final concentration, on ice overnight and then washed with FACS 3 times and immediately analyzed by flow cytometry (Becton-Dickinson, San Jose, CA, USA). For intracellular staining, samples were fixed and permeabilized before incubation with antibody. Antibodies used for flow cytometry were purchased.
from eBioscience (PE-anti-mouse CD4, APC-anti-mouse CD25, FITC-anti-mouse Foxp3, APC-anti-mouse CD8 and FITC-anti-mouse CD3). Data were analyzed with FlowJo software (Tree Star, Inc., Ashland, OR, USA).

**Statistical analysis.** Statistical comparisons of mean values were performed using the Student’s t-test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Potent in vitro cytokine release in response to SZU101.** To investigate the potency on murine TLR7 and the immunological activity of SZU101, bone marrow derived dendritic cells (BMDC), mouse nature killer cells (NK) and spleen lymphocytes isolated from BALB/c mice were stimulated with SZU101 at 5, 10, 20, 50 and 100 µM concentrations and LPS at 100 µM as positive control in vitro (Fig. 1). RAW264.7 cells were treated as mentioned above. The values are shown in Fig. 1A-D for IL6, IL12, TNF-α and IFN-γ of each cell type. Incubation of BMDC with SZU101 alone stimulated cytokine release (Fig. 1A). IL12 and TNF-α production was concentration-dependent from 5 to 50 µM, comparing with the concentration of LPS at 100 µM, both IL12 and TNF-α production of SZU101-treated group was higher than LPS positive control. For NK cell, we detected the release of TNF-α and INF-γ (Fig. 1B). We also used the mouse macrophage cell line RAW264.7 to evaluate the production of IL6 and TNF-α, with similar results (Fig. 1C). SZU101 was able to stimulate lymphocytes to release cytokines, which were related with adopted immunity, at the very high level compared with other innate immunity cells at the same concentration (Fig. 1D).

**Expression of TLR7 on immune cells and activation of NF-κB pathway.** To confirm that SZU101 was indeed the TLR7 ligand, we detected the expression of TLR7 on immune cells by western blot analysis. BMDC were treated with SZU101 to identify endogenous TLR7 expression for innate immune and spleen lymphocytes for adoptive immune. The western blot results showed that the expression of TLR7 increased after the SZU101 treatment in a concentration-dependent manner (Fig. 2B). We also detected the expression of TLR7 on the 4T1 cells. There was no expression of TLR7 on the 4T1 cells (Fig. 2A). For the activation of NF-κB pathway, NF-κBp65 was the key protein. NF-κB activation was observed by detected p65 expression on both cytoplasm and the nucleus (Fig. 2C).

**Intratumoral injection of SZU101 to 4T1 tumor-bearing BALB/c mice can reduce tumor growth.** 4T1 tumor-bearing BALB/c mice were treated every three days from day 7 to day 30 with SZU101 (n=5) or PBS (n=5). On day 30, the mice were sacrificed, the weight of spleen, and both sides of the tumor was measured. As shown in Fig. 3, the mean spleen weight of tumor-bearing BALB/c mice was higher than the healthy mice. The 4T1 tumor cells increased the spleen size (Fig. 3B).
In our experiment, there was a positive correlation between the weight of the spleen and the tumor. When the tumor was large, the spleen was also large. Although SZU101 could reduce both sides of the tumors, it could not reduce the size of the spleen efficiently. We injected SZU101 into the right tumor (we called it local tumor), and the result showned that SZU101 inhibited the local tumor (Fig. 3D). We also found that the growth of the left tumor was inhibited (Fig. 3C). The results showed that intratumoral SZU101 injection in local tumor was inhibited on the other side of the tumor.

Figure 2. SZU101 induced the expression of TLR in 4T1 cells and BMDC, and activation of NF-κB via TLR7. 4T1 cells (A) and BMDC (B) were stimulated with SZU101 from 0 to 50 µM for 12 h. BMDC (C) were treated with 0 and 10 µM SZU101 to detect the expression of P65 and IxBα. Cell lysates were assessed by western blotting using the primary antibodies: IxBα, NF-κBp65 and mTLR7.

Figure 3. In vivo antitumor efficiency of SZU101. (A) A picture of the tumors from one of the groups. After 30 days, mice from each group were scarified and the weight of spleen (B) and tumors (C and D) was measured. Error bars indicate SD. Data are representative of three independent experiments. *P<0.05, **P<0.01, respectively.
It has been demonstrated that the proportion of CD8 T cell not only in the TILs but also in the spleen was significant. To assess the ability of the SZU101 to activate CTLs, we determined the percentage of CD3⁺/CD8⁺ T cells, and the cytotoxicity rates of splenic lymphocytes on 4T1 tumor cells. As shown in Fig. 4A, the percentages of CD3⁺/CD8⁺ T cells in group SZU101 are remarkably higher than that in the control (Fig. 4B). The cytotoxicity rates of 4T1 cells induced by splenic lymphocytes in group SZU101 is higher than that in the control (Fig. 4C).

The humoral immune assay. Serum antibody titers against 4T1 tumor cells were determined by ELISA assay coating microtiter plates with whole protein of 4T1 tumor cells. As
shown in Fig. 5, 4T1 tumor cell antibody increased significantly in SZU101 group compared to control, but the control group also had high antibody titers (serum, and these responses were generally dominated by IgG2a, which is thought to reflect Th1-driven response. IgG2a titers were significantly different between SZU101-treated group and control group (Fig. 5D). Antibody-dependent cell-mediated cytotoxicity (ADCC) was determined by addition of serum samples and NK cells (cytotoxic effector cells) to 4T1 tumor cells (target cells), and measurement of released LDH activity (Fig. 5B). Compared with PBS control, control group was not significantly different tumor from cell lysis. However, SZU101 treated group induced significant cancer cell lysis compared with the other two groups. ADCC is primarily mediated by IgG1. IgG1 titers were increased in Fig. 5C.

**SZU101 effect on the frequency of intratumoral immune cell infiltration.** To examine the 4T1 tumor microenvironment in the treated mouse and to study if the treatment of tumor-bearing mice with SZU101 would lead to memory responses in the mice, we collected and processed distant tumors for analysis of infiltrating cells (Fig. 6). The percentage of T helper cells (CD4+/CD3+) in SZU101-treated mice significantly increased compared with untreated mice (Fig. 6A). We also found a strong increase of CD8+ T cells in the distant tumor (Fig. 6A). The CD4+/CD8+ ratio was reduced in SZU101 treated group (Fig. 6B). To determine the effect of SZU101 treatment on Tregs at the distant tumor site, CD25 and Foxp3 expression on CD4+ cells was assessed by flow cytometry. The distribution of CD25+, Foxp3+, or CD25+Foxp3+ (Treg) cells in the distant tumor are shown in Fig. 6C and D, respectively. In the distant tumor, the frequency of CD25+Foxp3+ cells was significantly reduced in SZU101-treated mice compared with (Fig. 6D). The untreated mice had 38.49±2.1% Tregs (Fig. 6C), whereas mice treated with SZU101 had fewer Tregs at the distant tumor site (27.17±3.6%, P<0.05) (Fig. 6C).

**Discussion**

For most solid tumors, surgery is still the main method, but small metastatic tumors cannot always be found and removed totally. Normally our immune systems are able to recognize tumor cells and remove them, but the tumor-bearing host loses the ability to recognize tumor cells as exogenous and fails to defend transformed cells. Immunotherapy attempts to stimulate the patient's own natural ability of the immune system to fight cancer, it is becoming increasingly widely used as more successful approaches are discovered (17). TLR agonists are of great interest in cancer immunotherapy (5). TLR agonists used as single agents especially when applied locally can effectively eradicate tumors due to their potent stimulation of innate and adaptive immunity as well as their effects on the tumor microenvironment (6,18). In the present study, we set up a local administration strategy to trigger systemic antitumor immune response on a mouse...
breast cancer model. The antitumor effect of SZU101 was associated with TLR7 activation of both innate immune cells and adaptive immune cells, especially reversal of tolerance in tumor microenvironment.

Non-specific innate immune cells play an important role in cancer therapy, particularly in the elimination of tumor metastases and small tumors. Activated NK cells have not only the capacity to detect changes in transformed cells, but also the responsibility for tumor rejection in a direct manner. Low natural killer (NK) activity has been reported as a high risk for developing malignancy. NK cells produce perforin to lyse tumor cells directly as shown in vivo and in vitro. TLR agonists can increase NK cell activity to enhance anti-body-dependent cell-mediated cytotoxicity (ADCC) and tumoricidal properties of NK cells (19). IFN-γ and TNF-α during tumor occurrence to further enhance their cytotoxicity and modulate the adaptive immune cells, such as dendritic cells and T cells. Tumor cells produce type 1 cytokines such as IFN-γ and TNF-α during tumor occurrence to further enhance their cytotoxicity and modulate the adaptive immune cells, such as dendritic cells and T cells. SZU101 stimulated NK cells to produce more TNF-α and IFN-γ than LPS control (21,22). In ADCC, the SZU101 group had higher ADCC activity than the other groups. There are two major kinds of macrophages: classical M1 and alternative M2 macrophages. The M1 macrophage can be activated by TLR7 agonists and IFN-γ, and secrete high levels of TNF-α, IL-6, which are markers of the M1 macrophage (23). We utilized RAW264.7 as the model in vitro. The results showed that TLR7 agonists activate RAW264.7 to produce high level of TNF-α and IL-6, which were markers of the M1 macrophage (Fig. 1C). In our study, SZU101 could not only elicit the non-specific antitumor responses but also strengthen the specific humoral and cellular immune responses. DCs play a crucial role in linking innate and adaptive immunity, and in the generation of a protective immune response against both infectious diseases and tumors. DCs are always immature in tumor microenvironment. Here, DCs were activated and matured by SZU101 in vitro, and we detected the secretion of IL12, IFN-γ and TNF-α at a high secretive level (Fig. 1A). The major function of DCs is as professional antigen presenting cells (APCs) to induce naïve T cell into protective CD8 T cells and CD4 T helper cells. Antigen delivery to DCs and maturation of DCs is relevant to antitumor success. Our CTL assay data showed that SZU101 stimulated systemic antitumor CD8 T cell response. SZU101 was injected into local tumor site (right flank), but the distant tumor was inhibited at the same time (Fig. 2). It implied that SZU101 may induce the CD8 T cells into T memory cells and CTL to aim to distant tumor. Intratumoral administration of TLR7 agonist generated systemic antitumor immunity and suppressed both injected and distant, uninjected wild-type B16F10 melanomas in a recent study. It showed that CD8 T cells, B cells, type I IFN, IFN-γ and plasmacytoid dendritic cells contributed to efficient tumor suppression (31). The microenvironment of solid tumor typically contains various cell subsets of the innate immune system (32). The immune cells have been shown to influence the immune system to promote either antitumor immunity, or tumor progression in the tumor microenvironment. Diederichsen et al showed a significantly higher 5-year survival in patients with a low CD4+/CD8+ ratio in the tumor infiltrating lymphocytes (33). Bloomfield et al investigated the potential of locally delivered imiquimod in a murine model of malignant mesothelioma (AB1-HA) with primary and distal tumors (dual tumor). They found imiquimod injection locally could stimulate an effective systemic antitumor response required both CD8 T cells and NK cells, but not CD4 T cells (34).

CD8+ T cells within cancer nests were shown to be better predictors of outcome than the same cells found in other areas of the tumor in NSCLC (35). Similarly, tumor specific CD8+ T cell activity determines colorectal cancer patient prognosis (36). In accordance with these results, our results showed that infiltration of CD8+ T cells increased, and CD4+/CD8+ T cells decreased in distant tumor by SZU101 injection (Fig. 6). As shown previously, SZU101 injection group delayed distant tumor growth. Clinical antitumor resistance has been correlated with increased intratumoral levels of immunosuppressive regulatory T cells (Tregs), and the phenotype of Tregs is CD4+/FOXP3+/CD25+ (37). We detected Tregs in the distant tumor, and representative dot plots are displayed in Fig. 6C. The results suggested that SZU101 reduced the number of Tregs in the distant tumor microenvironment. Some studies showed that Treg cell-mediated suppression could be overcome by the stimulation of TLRs on DCs (4). In a recent study, loxoribin, one of the TLR7 ligands, inhibited tumor growth in xenograft models of colon cancer and lung cancer by reversing Treg-mediated suppression via dendritic cells (DCs) (38).

In conclusion, the immunostimulatory properties of TLR ligands have been exploited to increase the efficacy of cancer immunotherapy. Our results confirmed that SZU101 could induce both innate and adaptive immune cells to strong Th-1-bias immune responses and the release of proinflammatory cytokines, such as TNF-α, IFN-γ, IL-6 and IL-12 in vitro. In a previous study, our group used SZU101 to treat tumors in a murine model of T cell lymphoma. SZU-101 could activated TLR7 NF-κB signaling in a TLR7-specific system at a low concentration of 1 μM after 6 h of stimulation in vitro. The anticancer therapies given directly into tumors may be more effective than given systemically, because local therapies could overcome natural suppressive factors in the tumor microenvironment, and induce systemic antitumor immunity (39).

For solid tumors, especially breast cancer, direct intratumoral injection is safe and effective (40). In the 4T1 mouse model of breast cancer, intratumoral administration of SZU101 generated systemic antitumor immunity and suppressed both injected and distant tumors. It implied that intratumor immunotherapy could induce local and systemic antitumor immunity by SZU101. Our findings in the present study provide an effective breast cancer immunotherapy by targeting tumor microenvironment.

Acknowledgements

We thank Professor Dennis Carson, University of California at San Diego, USA, for excellent technical guidance.
We also thank the National Natural Science Foundation of China (grant 81202396 and 81273374), the Science Foundation of Shenzhen (grant JCYJ2013032612757843 and JCYJ2013032611005734) and China Postdoctoral Science Foundation (grant 2013M54220) for providing financial support of the present study.

References